drugset / Trial / NCT03186638

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

NCT03186638

RandomizedParallel-groupDouble-blindSupportive care

Summary

This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.

Timeline

Start
2017-05-26
Primary completion
2022-03-30
Completion
2022-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule Oral